Ipamorelin is a short, lab-made peptide studied for prompting growth-hormone release. Human evidence is limited, and a bowel-surgery trial missed its main goal. It is coming soon to Promise.
Coming soon
You are on the list. We will email you when Ipamorelin becomes available — and nothing else. Joining is not a medical request, and no prescription has been issued.
That did not go through. Check the address and try again.
Ipamorelin is coming soon to Promise. Add your email and we'll let you know when visits open.
A licensed provider reviews every request; not everyone qualifies.
Every treatment gets its own online clinical questionnaire — your history, medications, and goals.
A real person goes through your history and takes the time to get it right before anything is decided.
If a treatment isn't right for your history, you'll hear that plainly. That review is the whole point.
Made for your prescription by a licensed U.S. pharmacy and shipped in temperature-safe packaging.
Your care team checks in after it arrives. Adjust with your provider, or cancel at any time.
Ipamorelin is easy to find online and hard to trust there. Promise works the way medicine is supposed to work — a clinician decides, a licensed pharmacy fills, and someone stays accountable to you.
Prescribed for you specifically, after a real look at your health history — never pulled off a shelf.
Your prescription is compounded for you by a licensed U.S. pharmacy — not a mystery vial from an unregulated website.
Temperature-safe shipping, follow-up check-ins, and a care team that answers — before and after your medication arrives.
Studied for growth-hormone signaling through the ghrelin receptor, a cell switch also used by a natural hormone. This peptide prompts release rather than supplying growth hormone.
Human research includes a healthy-volunteer study and a bowel-surgery trial that missed its main goal. Those settings leave long-term outcomes and safety unresolved.
When visits open, a licensed provider will weigh your health history, medicines, and the limited evidence before deciding whether a prescription is appropriate for you.
Ipamorelin is a lab-made peptide studied for signaling the body to release growth hormone. Human studies have measured that hormone response and tested gut recovery after surgery. They haven't established benefits for sleep, muscle, or healthy aging.
Ipamorelin is coming soon to Promise — add me to the list.
It is a short chain of five amino acids, the building blocks of proteins. Scientists call it a growth hormone secretagogue: a compound that prompts hormone release. It acts as a signal to the body rather than supplying growth hormone itself.
You may also see the name ipamorelin acetate. Acetate identifies a salt form of the molecule. The exact ingredient will be named on the prescription; the name alone doesn't tell you what preparation is being considered.
Within hormone and organ health, its research question concerns the body's own hormone release. That mechanism explains the interest. It doesn't establish what someone will feel or how their health will change.
The peptide activates the ghrelin receptor, a cell switch normally used by ghrelin. Ghrelin is a hormone involved in hunger and growth-hormone release. Researchers study the signal reaching the pituitary, a small gland beneath the brain that releases growth hormone.
Selectivity, meaning a more focused hormone response, drew early attention. Raun and colleagues' animal study in 1998 examined rat pituitary cells, rats, and pigs. In pigs, cortisol, a stress hormone, stayed at levels similar to those after the body's usual growth-hormone-release signal. Two older compounds raised cortisol in that experiment.
Those were animal findings. They do not establish fewer side effects in people or show that other hormones can never change during longer use.
A 1999 study in healthy men measured drug levels and growth hormone after an intravenous infusion, delivery into a vein. It recorded a brief episode of hormone release. This was a pharmacology study, meaning it tracked the drug and the body's response, rather than testing sleep or muscle outcomes.
The 2014 randomized bowel-surgery trial enrolled 117 adults; 114 were included in the safety and main outcome analyses. It compared intravenous ipamorelin with placebo, an inactive comparison. Patients and investigators did not know which was given.
The main question was how soon patients could tolerate a solid meal after surgery. The trial did not meet that main goal. Its additional outcome tests also found no significant difference between groups.
A separate completed surgical trial lists 320 participants but has no posted results. A completed record tells us that a study finished, not that the compound worked. These hospital studies do not establish long-term results for people considering it for other reasons.
Ipamorelin is not FDA-approved, and no FDA-approved product contains it. When it becomes available through Promise, it will be a compounded medication, prepared by a pharmacy for an individual prescription. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality.
The acetate form entered 503A Category 2 in 2023, a safety-concern category for ingredients considered for patient-specific compounding. Those nominations were later withdrawn. It remains in 503B Category 2, the separate safety-concern category for registered outsourcing facilities that compound medications.
FDA's safety summary for ipamorelin acetate reports serious adverse events, including death, in a study of intravenous ipamorelin for stomach movement. Its detailed review describes two deaths among ipamorelin-treated patients after bowel surgery and says it is unclear whether they were related to ipamorelin. FDA also flags possible immune reactions from peptide clumping or impurities. It has not identified safety information for certain other injection routes.
A licensed provider may still prescribe — that decision is between you and your doctor.
The side-effects guide discusses why short hospital studies cannot supply a reliable picture of longer outpatient use.
MK-677, also called ibutamoren, is an oral small molecule studied at the same ghrelin receptor. Oral means taken by mouth. It has different chemistry and its own human studies. Sharing a receptor doesn't make the two compounds interchangeable or let one borrow the other's evidence.
Sermorelin copies growth-hormone-releasing hormone, the body's own release signal, and acts through a different receptor. It reaches the same gland through a separate input; the sermorelin and ipamorelin comparison walks through the difference.
CJC-1295 / Ipamorelin and Tesamorelin / Ipamorelin are blends that add another peptide to this one. Promise offers the CJC-1295 / Ipamorelin blend by prescription; Tesamorelin / Ipamorelin is coming soon. The studies described above examined ipamorelin alone. They cannot establish the safety or results of either combination.
When visits open, the process will begin with an intake questionnaire written for this compound. It will cover your health history, current medicines and supplements, and the reason for your request. A provider may ask for more information or lab work before deciding.
A licensed provider will read your answers and decide whether to prescribe.
If it is prescribed, a licensed U.S. pharmacy will compound and dispense the medication. Follow-up check-ins from your care team will keep the plan under review. Your provider sets any protocol; Promise does not publish dosing.
Ipamorelin is a lab-made chain of five amino acids, the building blocks of proteins. It is studied for prompting growth-hormone release through the ghrelin receptor, a cell switch also used by a natural hormone. Human studies have measured hormone responses and tested gut recovery after surgery, without establishing general wellness benefits.
Yes. When visits open, Ipamorelin will be prescribed by a licensed provider after a review of your health history and compounded for you by a licensed U.S. pharmacy. It will not be a product labeled for laboratory use. The provider may decline if it isn't appropriate.
A prescription isn't automatic. Once visits open, a licensed provider will review your request and decide whether the compound is appropriate. They may request more information or decline. Completing the questionnaire or joining the list will not replace that medical decision.
No. Ipamorelin is not FDA-approved, and no FDA-approved product contains it. The formulation Promise will offer is a compounded medication, which is not reviewed by the FDA for safety, effectiveness, or quality. A prescription will depend on an individual provider review.
Not yet. Ipamorelin is coming soon to Promise — add me to the list on this page and we'll email you when visits open. The list is for updates about availability. Once visits open, a medical evaluation will be required before any prescription is issued.
They act at the same ghrelin receptor but are different compounds. Ipamorelin is a peptide, a short chain of amino acids. MK-677, also called ibutamoren, is an oral small molecule rather than a peptide. Each has its own study record, so findings about one cannot establish the other's safety or results.
It shows a hormone response in healthy volunteers and an unsuccessful main outcome in a bowel-surgery trial. The selective hormone reputation comes from animal work. FDA also reports serious adverse events in an intravenous study, including two deaths after bowel surgery; its review says it is unclear whether they were related to ipamorelin. These data do not establish long-term safety or benefits for sleep, muscle, or healthy aging.
Ipamorelin sold without a prescription may be labeled for laboratory use and come without a reviewing provider or patient-specific pharmacy dispensing. When visits open, a Promise prescription will require a licensed provider review, a licensed U.S. compounding pharmacy, and follow-up check-ins from your care team. That clinical process will not erase the gaps in evidence.
Other Hormone & Organ Health options a provider may consider.
Hormone & Organ Health
GH secretagogue for sleep, recovery, and vitality.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Hormone & Organ Health
A two-peptide blend pairing a GHRH analog with a selective growth hormone secretagogue, studied for supporting the body's own pulsed release rather than supplying growth hormone.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Hormone & Organ Health
A stabilized analog of growth-hormone-releasing hormone, and the most clinically studied peptide in this group — the research has centered on visceral abdominal fat.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
The latest from the Promise team on Ipamorelin.
The quarter brought a new WADA list, online-product notices and an evidence review. The two molecules still have different FDA records and limited human outcome data.
IGF-1 levels by age usually decline after early adulthood. Your lab's range puts the number in context; trial increases aren't treatment targets.
Masayasu Kojima, Kenji Kangawa and colleagues identified ghrelin in 1999. Earlier peptide and receptor discoveries set up the finding; appetite studies followed.
Type a treatment, a goal, or a question.